Phase II Study of Single Agent Regorafenib in Patients With Advanced/Metastatic Neuroendocrine Tumors
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Regorafenib (Primary)
- Indications Carcinoid tumour; Pancreatic cancer
- Focus Therapeutic Use
- 18 Apr 2017 Planned End Date changed from 1 Oct 2019 to 16 Aug 2020.
- 18 Apr 2017 Planned primary completion date changed from 1 Oct 2018 to 16 Aug 2019.
- 18 Apr 2017 Status changed from not yet recruiting to recruiting.